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Abstract
The ordered assembly of tau protein into abnormal filaments is a defining characteristic of Alzheimer’s disease (AD) and 
other neurodegenerative disorders. It is not known if the structures of tau filaments vary within, or between, the brains of 
individuals with AD. We used a combination of electron cryo-microscopy (cryo-EM) and immuno-gold negative-stain 
electron microscopy (immuno-EM) to determine the structures of paired helical filaments (PHFs) and straight filaments 
(SFs) from the frontal cortex of 17 cases of AD (15 sporadic and 2 inherited) and 2 cases of atypical AD (posterior cortical 
atrophy). The high-resolution structures of PHFs and SFs from the frontal cortex of 3 cases of AD, 2 sporadic and 1 inher-
ited, were determined by cryo-EM. We also used immuno-EM to study the PHFs and SFs from a number of cortical and 
subcortical brain regions. PHFs outnumbered SFs in all AD cases. By cryo-EM, PHFs and SFs were made of two C-shaped 
protofilaments with a combined cross-β/β-helix structure, as described previously for one case of AD. The higher resolution 
structures obtained here showed two additional amino acids at each end of the protofilament. The immuno-EM findings, 
which indicated the presence of repeats 3 and 4, but not of the N-terminal regions of repeats 1 and 2, of tau in the filament 
cores of all AD cases, were consistent with the cryo-EM results. These findings show that there is no significant variation 
in tau filament structures between individuals with AD. This knowledge will be crucial for understanding the mechanisms 
that underlie tau filament formation and for developing novel diagnostics and therapies.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegen-
erative disorder [33]. The vast majority of cases are spo-
radic, with age being the main predisposing factor. Inherit-
ance of the ε4 allele of the apolipoprotein E gene (APOE) is 
a major genetic risk factor for sporadic AD [37]. Dominantly 
inherited forms of AD, which are caused by mutations in 
the amyloid precursor protein gene (APP) [17, 29] and the 
presenilin genes (PSEN1 and PSEN2) [26, 35], account for 
less than 1% of cases. No mechanism-based therapies exist.
All cases of AD are characterised by abundant intraneu-
ronal neurofibrillary lesions of filamentous tau [4, 22, 41, 
42] and extracellular deposits of filamentous β-amyloid 
(Aβ) [16, 27] in the cerebral cortex and other brain regions. 
Atypical forms of AD differ from typical forms by clinical 
presentation and the brain areas most severely affected by 
neurofibrillary lesions and Aβ deposits [15]. Despite being 
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made of unrelated proteins, tau and Aβ filaments share a 
cross-β architecture characteristic of amyloids [2, 16]. Fila-
mentous tau inclusions, in the absence of Aβ deposits, define 
a number of other neurodegenerative diseases [18]. Six tau 
isoforms are expressed in normal adult human brain: three 
isoforms have four microtubule-binding repeats (R1, R2, R3, 
R4; 4R tau) and three isoforms lack the second repeat (3R 
tau). Tau filaments of AD are composed of all six isoforms 
[20].
Neurofibrillary lesions consist of tangles in cell bodies, 
neuropil threads in the processes of nerve cells, and dys-
trophic neurites associated with plaques. The accumulation 
of neurofibrillary lesions in brain follows a stereotypical pat-
tern that correlates with atrophy and cognitive deficits [3]. It 
follows that an understanding of the ordered assembly of tau 
into filaments is essential for diagnosis and therapy. Tau fila-
ments from AD brain adopt two characteristic morphologies. 
Paired helical filaments (PHFs) constitute the major spe-
cies; they have a helical crossover distance of approximately 
70 nm, with pronounced variations in projected widths from 
7 to 15 nm. Straight filaments (SFs), which have a similar 
crossover distance, but a constant width of approximately 
10 nm, are in the minority [8].
The structures of PHFs and SFs extracted from the frontal 
cortex of an individual with sporadic AD were previously 
determined using electron cryo-microscopy (cryo-EM) [14]. 
PHFs and SFs were found to be ultrastructural polymorphs, 
which share two identical protofilaments, but differ in their 
inter-protofilament packing. Each C-shaped protofilament 
adopted a combined cross-β/β-helix structure comprising 
residues 306–378 of human tau (in the numbering of the 
441 residue isoform), i.e., R3, R4, and 10 amino acids fol-
lowing R4. Cryo-EM was also used to determine the struc-
tures of tau filaments from the frontotemporal cortex of an 
individual with Pick’s disease (PiD) [12], a frontotemporal 
dementia with tau filaments made of 3R tau. The ordered 
core of tau filaments from PiD was made of a single proto-
filament with an elongated cross-β structure, comprising 
residues K254–F378 of tau (but lacking V275–S305 of R2). 
Distinct conformers of aggregated tau thus exist in human 
tauopathies.
It is not known if the structures of tau filaments vary 
within, or between, the brains of individuals with AD. This 
knowledge is vital for the development of therapies targeting 
tau assembly and the design of diagnostic ligands. It is also 
essential for understanding the mechanisms underlying tau 
filament formation and propagation.
Here, we used cryo-EM to determine the structures of 
tau filaments from two additional cases of sporadic AD and 
one case of dominantly inherited disease (V717F mutation 
in APP). Since cryo-EM is too low throughput to study a 
large number of cases, we also used immuno-gold nega-
tive-stain electron microscopy (immuno-EM) to determine 
the morphologies and tau repeat composition of the core of 
PHFs and SFs from frontal cortex of the four cases used for 
cryo-EM, an additional 12 cases with the typical form of 
sporadic AD, and one more case with dominantly inherited 
disease. We also used immuno-EM to study tau filaments 
from temporal, occipital, and cingulate cortices, as well as 
from thalamus, substantia innominata, and putamen of AD 
case 1 used previously for cryo-EM [14]. Immuno-EM was 
performed as well on tau fillaments extracted from frontal 
and occipital cortices of two cases of posterior cortical atro-
phy (PCA). PCA is an atypical form of sporadic AD with the 
early visual dysfunction and neurodegeneration of posterior 
cortical regions [1, 9]. Our immuno-EM results are consist-
ent with the core of PHFs and SFs from all AD cases and 
brain regions examined comprising R3 and R4 of tau, while 
our cryo-EM structures demonstrate that PHFs and SFs from 
frontal cortex of the three new cases of AD are like those 
we previously reported [14], indicating the existence of a 
common tau fold in AD.
Materials and methods
Extraction of tau filaments
Sporadic cases of typical AD were selected according to 
several criteria, including a wide spread in the ages at death 
of patients and in the post-mortem intervals (time between 
death and brain autopsy), a tau pathology of Braak stage 
6, and no or only mild co-pathologies. Inherited cases of 
typical AD were chosen based on the presence of a V717F 
mutation in APP and sporadic cases of atypical AD exhib-
ited a clinical and neuropathological picture of PCA. Neu-
rohistology and immunohistochemistry were carried out as 
described [36].
Sarkosyl-insoluble material was extracted according to 
[20]. Approximately 6 g frontal cortex was used for cryo-EM 
and 0.6 g from each brain region studied for immuno-EM. 
The pelleted sarkosyl-insoluble material was resuspended 
in 10 mM Tris–HCl pH 7.4, 800 mM NaCl, 5 mM EDTA, 
and 1 mM EGTA, with a final concentration of 10% (w/v) 
sucrose at 750 μl per g tissue, followed by centrifugation at 
20,100g for 30 min at 4 °C. The resulting supernatant was 
centrifuged at 100,000g for 1 h at 4 °C. The pellet was resus-
pended in 20 mM Tris–HCl pH 7.4 containing 100 mM NaCl 
at 250 μl/g tissue and centrifuged at 100,000g for 30 min at 
4 °C. The final pellet was resuspended in buffer at 15 μl/g 
tissue for cryo-EM and 150 μl/g tissue for immuno-EM.
Electron cryo‑microscopy
Extracted tau filaments were applied to glow-discharged 
holey carbon grids (Quantifoil Au R1.2/1.3, 300 mesh) and 
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plunge-frozen in liquid ethane using an FEI Vitrobot Mark 
IV. Images were acquired on a Gatan K2-Summit detector in 
counting mode using an FEI Titan Krios at 300 kV. A GIF-
quantum energy filter (Gatan) was used with a slit width of 
20 eV to remove inelastically scattered electrons. Further 
details are given in Online Resource 2.
Helical reconstruction
Movie frames were corrected for gain reference, motion-
corrected, and dose-weighted using MOTIONCOR2 [44]. 
Aligned, non-dose-weighted micrographs were used to 
estimate the contrast transfer function in Gctf [43]. All 
subsequent image-processing steps were performed using 
helical reconstruction methods in RELION 2.1 [24, 34]. 
Filaments were picked manually. For case 2, PHFs and SFs 
were picked as separate data sets. For cases 3 and 16, fila-
ments were collected as a single data set; PHFs and SFs were 
subsequently separated by reference-free 2D classification 
of segments comprising an entire helical crossover. PHF and 
SF segments were re-extracted using box sizes of 200 or 
270 pixels and an inter-box distance of approximately 14 
Å. Reference-free 2D classification was performed and seg-
ments contributing to suboptimal 2D class averages were 
discarded. For cases 2 and 16, the initial 3D models were 
constructed de novo from 2D class averages of segments 
comprising entire helical crossovers, and low-pass filtered to 
40 Å. For case 3, the PHF and SF reconstructions from case 
1 (PDB accession numbers 503L and 503T) [14] were low-
pass filtered to 10 Å and used as the initial 3D models. 3D 
classification with local optimisation of helical twist and rise 
was performed to remove segments contributing to subopti-
mal 3D class averages, and the selected segments were used 
for 3D auto-refinement with optimisation of the helical twist. 
A value of 10% was used for the helical z percentage param-
eter. For case 16, particle polishing was performed, followed 
by further 3D auto-refinement. The final reconstructions 
were sharpened using the standard post-processing proce-
dures in RELION and helical symmetry was imposed using 
the RELION helix toolbox [24]. Finally, overall resolution 
estimates were calculated from Fourier shell correlations at 
0.143 between two independently refined half-maps, using 
phase randomization to correct for the convolution effects 
of a generous, soft-edged solvent mask [5]. Local resolu-
tion estimates were obtained using the same-phase rand-
omization procedure, but with a soft spherical mask that was 
moved over the entire map. For further details, see Online 
Resource 2. Cryo-EM maps for case 2 have been depos-
ited in the Electron Microscopy Data Bank (EMDB) under 
accession numbers EMD-0259 for PHF and EMD-0260 for 
SF.
Model building and refinement
Compared to [14], the PHF and SF reconstructions from 
the frontal cortex of AD patient 2 showed clear densities 
corresponding to two additional residues at the N-terminus 
(G273 and K274 from 3R tau; or G304 and S305 from 4R 
tau) and two residues at the C-terminus (R379 and E380) 
of the protofilament core. These residues were added to the 
PHF and SF models from the frontal cortex of AD patient 1 
[14] (PDB accession numbers 503L and 503T) using COOT 
[11]. The new models were then refined against the PHF 
and SF reconstructions from patient 2 using targeted real-
space refinement in COOT. The models were subsequently 
translated to give stacks of three consecutive monomers 
to preserve nearest-neighbour interactions for the middle 
chains in subsequent Fourier space refinements in REFMAC 
[30]. Local symmetry restraints were imposed to keep all 
β-strand rungs identical. Side-chain clashes were detected 
using MOLPROBITY [6] and corrected by iterative cycles 
of real-space refinements in COOT and Fourier space refine-
ments in REFMAC. Separate model refinements were per-
formed against single half-maps, and the resulting models 
compared with the other half-maps to confirm the absence of 
overfitting. The final models were stable in refinements with-
out additional restraints. Further details are given in Online 
Resource 3. Refined atomic models for case 2 have been 
deposited in the Protein Data Bank (PDB) under accession 
numbers 6HRE for PHF and 6HRF for SF.
Immuno‑gold negative‑stain electron microscopy
Extracted tau filaments were deposited on glow-discharged 
400 mesh formvar/carbon film-coated copper grids (EM 
Sciences CF400-Cu) for 40  s, blocked for 10 min with 
PBS + 0.1% gelatin, and incubated with primary antibody 
(1:50) in blocking buffer, essentially as described [20]. 
Primary antibodies were BR136 (raised against residues 
244–257) [12], Anti-4R (raised against residues 275–291, 
with D279) [10], BR135 (raised against residues 323–335) 
[21], and TauC4 (raised against residues 354–369) [38]. 
Where stated, grids were incubated for 5 min with 0.4 mg/
ml pronase (Sigma) in PBS at room temperature and 
washed with blocking buffer, prior to blocking. Following 
incubation with primary antibodies, grids were washed with 
blocking buffer and incubated with 10 nm gold-conjugated 
anti-rabbit IgG (Sigma) diluted 1:20 in blocking buffer. The 
grids were then washed with water and stained with 2% ura-
nyl acetate for 40 s. Images were acquired at 11,000 × and 
15,000 ×, with a defocus value of -1.4 μm with Gatan Orius 
SC200B or Gatan Ultrascan 1,000 CP CCD detectors using 
a Tecnai G2 Spirit at 120 kV. To distinguish non-specific 
background levels of isolated gold beads from specific 
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labelling of the filaments, we only considered filaments with 
more than six gold beads to be positively labelled.
Whole‑exome sequencing
DNAs of the AD cases were sequenced at the Center for 
Medical Genomics of Indiana University School of Medi-
cine. Target enrichment made use of the SureSelectXT 
human all exon library (V6, 58 Mb, Agilent) and high-
throughput sequencing was carried out using a HiSeq4000 
(2 × 75 bp paired-end configuration, Illumina). Bioinformat-
ics analyses were performed as described [13]. There were 
no pathogenic mutations in MAPT. Table 1 summarises the 
findings for APP, PSEN1, PSEN2, and APOE.
Table 1  Cases of Alzheimer’s 
disease
Wild-type (wt), no known pathogenic mutations were detected. Cases 1, 2, 3, and 16 were used for 
cryo-EM (highlighted in yellow)
PMI post-mortem interval
Fig. 1  Cryo-EM densities and atomic models of PHFs and SFs 
from the frontal cortex of AD case 2. PHFs and SFs from case 2 are 
resolved to 3.2 Å and 3.3 Å, respectively. Sharpened, high-resolution 
maps are shown in blue (PHF) and green (SF). Unsharpened 4.5 Å 
low-pass filtered densities are shown in grey. The models comprise 
G273-E380 of 3R tau and G304-E380 of 4R tau
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Results
Electron cryo‑microscopy
We first used cryo-EM to image tau filaments extracted from 
the frontal cortex of an individual with sporadic AD (Fig. 1, 
case 2 in Table 1). PHFs and SFs were present in a ratio of 
approximately 4:1. Using helical reconstruction in RELION 
[24], we determined the structures of PHFs to 3.2 Å and of 
SFs to 3.3 Å resolution (Fig. 1, Online Resources 1, 2 and 
3). As reported before [14] for filaments extracted from a 
case of sporadic AD (case 1 in Table 1), the core structure 
comprised V306-F378 of tau in a combined cross-β/β-helix, 
C-shaped fold (Online Resource 4). Moreover, the higher 
resolution structures of tau filaments reported here showed 
additional densities corresponding to G304 and S305 from 
R2 (or G273 and K274 from R1), as well as R379 and E380 
from the sequence after R4, which were not as well resolved 
in the structures from AD case 1 [14]. The first β-strand 
of the protofilament structure begins at K274 of R1 or at 
S305 of R2 and ends at K311, whereas the eighth β-strand 
extends from N368–E380. Weaker densities extending from 
the N- and C-terminal regions of the core, described for fila-
ments extracted from AD case 1 [14], were also observed, as 
were the densities interacting with the sidechains of K317, 
T319, and K321. In PHFs, the side chains of K331 from one 
protofilament projected between the side chains of Q336 
and E338 of the other protofilament, suggesting additional 
interactions that stabilize the protofilament interface. Moreo-
ver, in the protofilament interface of the PHF, the higher 
resolution structure revealed the presence of extra densities 
extending from the side chains of K331 on one protofilament 
to the backbone atoms of V337 of the other protofilament 
(Online Resource 5). This density may correspond to a water 
molecule or a post-translational modification of K331, such 
as mono-methylation.
We also used cryo-EM to determine the structures of tau 
filaments extracted from the frontal cortex of a third indi-
vidual with sporadic AD (case 3 in Table 1) and an indi-
vidual with dominantly inherited AD (mutation V717F in 
APP; case 16 in Table 1). In both individuals, PHFs and 
SFs were present in a ratio of approximately 4:1. Despite 
lower resolution, the structures of PHFs and SFs were the 
same as those of tau filaments from cases 1 and 2 (Fig. 2, 
Online Resource 2). A side-by-side comparison of PHF and 
SF reconstructions from cases 1–4 showed the presence of 
extra densities bordering the solvent-exposed side chains of 
R349 and K375, and of H362 and K369 within each C-shape 
(Fig. 2, Online Resource 2).
Immuno‑gold negative‑stain electron microscopy
To extend our analysis to a larger number of AD cases 
and additional brain regions from the first case studied by 
Fig. 2  Cryo-EM structures of PHFs and SFs from the frontal cortex 
of AD cases 1, 2, 3, and 16. All structures show identical pairs of 
C-shaped protofilaments and the same inter-protofilament packing in 
PHFs and SFs. Cases 1, 2, and 3 had sporadic AD, whereas case 16 
had inherited AD (mutation V717F in APP). The filament structures 
of case 1 are from (14); the structures from cases 2, 3, and 16 are first 
described here. All cases had a majority of PHFs and a minority of 
SFs. Yellow arrows indicate the extra densities, which are present in 
PHFs and SFs from all four cases, bordering the solvent-exposed side 
chains of R349 and K375, and of H362 and K369. Scale bar, 50 Å
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cryo-EM [14], we used immuno-EM to assess filament 
morphologies and the labelling of extracted filaments by 
repeat-specific anti-tau antibodies. We used antibodies 
specific for residues 244–257 of R1 (BR136), residues 
275–291, with D279, of R2 (Anti-4R), residues 323–335 
of R3 (BR135), and residues 354–369 of R4 (TauC4) 
of tau, all of which label tau bands on Western blots of 
Fig. 3  Immuno-EM of tau filaments from the frontal cortex of spo-
radic and inherited AD cases. a 441 amino acid isoform of human 
tau and epitopes of repeat-specific antibodies. The amino-terminal 
inserts are labelled N1 and N2, with the microtubule-binding repeats 
being R1–R4. Black lines indicate the epitopes of antibodies BR136 
(R1), Anti-4R (R2), BR135 (R3) and TauC4 (R4) that were used 
for immuno-EM. b, c Representative images from sporadic (b) and 
inherited (c) cases of AD before (−) and after (+) pronase treatment. 
Frontal cortex from 15 cases of typical sporadic AD and two cases of 
inherited AD (mutation V717F in APP) were studied. Tau filaments 
from all the cases were decorated by BR136 and Anti-4R before pro-
nase treatment, but not by BR135 or TauC4. Pronase treatment abol-
ished labelling by BR136 and Anti-4R.  PHFs were in the majority 
and SFs in the minority. Scale bar, 100 nm
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dispersed filaments [12, 14] (Fig. 3a, Online Resource 
6). However, linear epitopes buried in the cores of tau 
filaments are not accessible to antibodies, in contrast to 
epitopes located in the fuzzy coat, which give positive 
labelling [14]. Moreover, pronase treatment removes the 
fuzzy coat, abolishing this positive labelling.
Besides tau filaments from the four cases analysed by 
cryo-EM (cases 1–3 and 16), we also looked at tau filaments 
from the frontal cortex of 12 additional cases of sporadic 
AD (patients 4–15) and one more case of dominantly inher-
ited AD (V717F in APP, patient 17) (Table 1). In all cases, 
extracted filaments consisted of a majority of PHFs and a 
minority of SFs. By negative-stain EM, antibodies BR136 
and Anti-4R decorated the filaments from all cases before, 
but not after, pronase treatment. By contrast, BR135 and 
TauC4 did not decorate PHFs or SFs from the frontal cor-
tex of cases 4–15 or case 17, either before or after pronase 
treatment (Fig. 3b, c, Online Resource 7). This suggests that 
residues 323–335 of R3 and 354–369 of R4 of tau are in the 
filament core, whereas residues 244–257 of R1 and 275–291 
of R2 of tau lie in the fuzzy coat. These findings are con-
sistent with the presence of the same tau sequences in the 
core of tau filaments in the frontal cortex of all the analysed 
cases (17 cases of sporadic AD and 2 cases of dominantly 
inherited AD).
To extend our findings to different brain regions, we 
studied tau filaments from temporal, occipital, parietal, 
and cingulate cortices, as well as from thalamus, substantia 
innominata, and putamen of case 1 of sporadic AD, whose 
frontal cortex was used for cryo-EM and immuno-EM 
(Figs. 2, 4, Online Resource 7). In all regions, a majority of 
PHFs and a minority of SFs were in evidence. By immuno-
EM, filaments were labelled by BR136 and Anti-4R before, 
but not after, pronase treatment, and not by BR135 or TauC4. 
This indicates that, in all brain regions examined, residues 
323–335 of R3 and 354–369 of R4 are present in the core of 
the filaments, as in all cases of AD examined.
PCA is an atypical form of sporadic AD with abundant 
tau filaments in the occipital cortex [9]. As in typical AD, 
a majority of PHFs and a minority of SFs were present in 
frontal and occipital cortices of cases 18 and 19. Tau fila-
ments were decorated by BR136 and Anti-4R, but not by 
BR135 or TauC4 (Fig. 5, Online Resource 7). Following 
pronase treatment, the decoration by BR136 and Anti-4R 
was lost, suggesting also, for these cases, the presence of 
residues 323–335 of R3 and 354–369 of R4 of tau in the 
filament core.
Discussion
The cryo-EM structures of the core of PHFs and SFs from 
the frontal cortex of four typical cases of AD (three sporadic 
and one inherited) showed a common protofilament fold. 
The filament structures from case 1 were reported in [14]. 
The structures from case 2 were of higher resolution than 
Fig. 4  Immuno-EM of tau filaments from the putamen of AD case 
1. Representative images before (−) and after (+) pronase treatment. 
In addition to frontal cortex and putamen, temporal cortex, parietal 
cortex, cingulate cortex, thalamus, and substantia innominata from 
case 1 were also analysed. Tau filaments from all brain regions were 
decorated by BR136 and Anti-4R before pronase treatment, but not 
by BR135 or TauC4. Pronase treatment abolished labelling by BR136 
and Anti-4R. PHFs were in the majority and SFs in the minority. 
Scale bar, 100 nm
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those of case 1, but the resolutions of structures from cases 
3 and 16 were lower. The achievable resolution of filament 
structures from a given AD case is mainly determined by the 
number of filaments that can be extracted from brain. PHFs 
and SFs from all four cases were made of two protofilaments 
with a common cross-β/β-helix C-shaped architecture. The 
interfaces between the two protofilaments of both PHFs and 
SFs were the same in all four cases. These findings show that 
the PHF and SF structures are identical between sporadic 
(irrespective of APOE genotype) and inherited cases of AD.
The higher resolution cryo-EM structures of PHFs and 
SFs from case 2 showed the presence of two additional resi-
dues at the N-terminus, and two additional residues at the 
C-terminus of the ordered core of the protofilament. At the 
C-terminus, these residues were R379 and E380 from the 
sequence after R4. Because AD filaments contain a mixture 
of all six brain tau isoforms [20], the additional density at 
the N-terminus arose from a mixture of 3R and 4R tau iso-
forms. It comprised G304 and S305 from R2 in 4R tau, and 
G273 and K274 from R1 in 3R tau. The additional cryo-EM 
density at the N-terminus was consistent with the presence 
of a glycine and a mixture of a partially disordered serine 
and a lysine. Weaker densities extended from the N- and 
C-terminal regions of the core, which could accommodate 
additional tau residues in more dynamic or transiently occu-
pied structures, as reported in the structures from AD case 
1 [14]. Densities interacting with the sidechains of K317, 
T319, and K321 were also observed, which we previously 
suggested could be residues 7EFE9 of tau, giving rise to the 
discontinuous MC1 epitope [14]. Similar densities were also 
found in the structures of tau filaments from PiD [12].
Since cryo-EM is a low-throughput technique, we also 
used immuno-EM to study tau filaments from the frontal 
cortex of the four cases used for cryo-EM, plus another 15 
cases of AD. They represented both typical and atypical 
cases, and a variety of APOE genotypes. It is important to 
combine both techniques, because immuno-EM does not 
provide high-resolution structural information. In all cases, 
PHFs were in the majority and SFs in the minority. They 
were decorated by BR136 and Anti-4R, but not by BR135 
or TauC4, indicating that R3 and R4 form part of the fila-
ment core, whereas the N-terminal regions of R1 and R2 
lie within the fuzzy coat. Importantly, the immuno-EM 
labelling of tau filaments from the cases used for cryo-EM 
was indistinguishable from that of the other cases studied, 
including PCA, an atypical form of sporadic AD. Moreover, 
for case 1, brain regions other than frontal cortex, including 
subcortical areas, gave an identical decoration pattern and 
contained a majority of PHFs. Thus, the core of all tau fila-
ments contained R3 and R4.
The cryo-EM structures of tau filaments from individuals 
with end-stage AD do not tell us how the assembly process 
may have started. Since tau is hydrophilic [40], it is not sur-
prising that the formation of filaments by recombinant pro-
tein requires cofactors, such as heparin [19, 31]. Negatively 
charged cofactors and/or chemical modifications of tau may 
Fig. 5  Immuno-EM of tau filaments from the occipital cortex of PCA 
cases. Representative images before (−) and after (+) pronase treat-
ment. Occipital cortex from two cases of PCA, an atypical form of 
sporadic AD, was studied. Tau filaments from both cases were dec-
orated by BR136 and Anti-4R before pronase treatment, but not by 
BR135 or TauC4. Pronase treatment abolished labelling by BR136 
and Anti-4R.  PHFs were in the majority and SFs in the minority. 
Scale bar, 100 nm
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be needed for the ordered assembly of tau into filaments in 
human brain. The extra densities bordering the positively 
charged side chains of solvent-exposed amino acids in the 
cryo-EM maps of PHFs and SFs from all four cases may be 
such factors. Once a seed has formed, tau may be able to 
assemble and propagate [23, 28], which may also require 
such cofactors and/or chemical modifications. In a mouse 
model transgenic for human mutant P301S tau, short tau fila-
ments had the greatest seeding activity in non-neuronal cells 
expressing full-length human P301S tau [25]. It remains to 
be seen if this is also the case for AD.
The present findings suggest that the filament cores from 
multiple brain regions of sporadic and inherited cases of 
AD, as well as of atypical sporadic cases, contain identical 
tau sequences. They are consistent with the existence of a 
common fold for tau filaments in AD. Tau is an intracellu-
lar protein. Its accumulation may involve mechanisms that 
differ from those that facilitate the seeding of proteins that 
form amyloids extracellularly. For  PrPSc and Aβ, structurally 
heterogeneous assemblies, also referred to as conformational 
clouds, have been described [7, 32, 39]. Knowledge of the 
structural differences between assemblies of  PrPSc and Aβ 
must await the determination of their high-resolution struc-
tures from brain.
Distinct tau filament folds are found in specific diseases. 
The cryo-EM structures of tau filaments from the brain of 
an individual with PiD revealed that they adopt a fold that 
is different from the AD fold [12]. Immuno-EM results for 
eight additional cases of PiD revealed a common ordered 
filament core comprising most of R1, as well as the whole 
of R3 and R4. Therefore, specific molecular conformers of 
aggregated tau may define different diseases, without there 
being a significant variation in filament structures between 
individuals with a given disease. This understanding will 
inform the design of diagnostic ligands of higher specificity 
and the development of therapies targeting tau assembly. It 
remains to be seen if what is true of AD and PiD also applies 
to other human tauopathies.
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